Sunitinib (Sutent) and regorafenib (Stivarga), known as the multi-target kinase inhibitors for VEGFR, PDGFR, Kit, etc., were approved for the second and third lines of GIST treatment, respectively. The gene discussed is KDR; the disease is gastrointestinal stromal tumor.